Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute for Medical Research, Tanzania | OTHER_GOV |
| University of Zambia | OTHER |
| Sokoine University of Agriculture | OTHER |
Not provided
Not provided
Not provided
Not provided
This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy.
Neurological symptom/sign and cyst resolution, quality of life, accuracy and performance of serological T. solium diagnostics and NCC-specific immunological parameter will be followed up at multiple time points in the study. The final assessment will be done six months after the end of anthelmintic treatment. This study aims to guide treatment of NCC in sub-Saharan Africa by identifying factors that are associated with treatment outcomes.
The factors that cause some people to fail complete resolution of all cysts and/or symptoms/signs are unknown.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Resolution of lesions | The number of active cysts identified by CT scan after treatment | Change in number of active cysts from before treatment to six months after treatment termination |
| Symptom/sign frequency | The percentage of participants who exhibit a neurological symptom/sign of NCC: chronic/severe progressive headache or epileptic seizures. | Change of symptom/sign frequency from before treatment to six months after treatment termination |
| Measure | Description | Time Frame |
|---|---|---|
| Health-related Quality of Life (all patients): WHOQOL-Bref questionnaire | The change in participants' self-reported quality of life from before to after treatment, as measured by the WHOQOL-Bref questionnaire (in all participants) [World Health Organization Quality of Life questionnaire; consisting of 26 items]. Quality of life is assessed by four domains - physical health, psychological, social relationships and environment. In each domain a score of 0 to 100 can be achieved. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). Domains are not summarised to an overall score. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with active, symptomatic neurocysticercosis in rural areas in Tanzania and Zambia
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institute of Medical Research | Dar es Salaam | Tanzania |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36961623 | Result | Stelzle D, Makasi C, Schmidt V, Trevisan C, Van Damme I, Ruether C, Dorny P, Magnussen P, Zulu G, Mwape KE, Bottieau E, Prazeres da Costa C, Prodjinotho UF, Carabin H, Jackson E, Fleury A, Gabriel S, Ngowi BJ, Winkler AS. Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. Infection. 2023 Aug;51(4):1127-1139. doi: 10.1007/s15010-023-02021-y. Epub 2023 Mar 24. |
| Label | URL |
|---|---|
| Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D020019 | Neurocysticercosis |
| ID | Term |
|---|---|
| D020809 | Central Nervous System Helminthiasis |
| D020807 | Central Nervous System Parasitic Infections |
| D002494 | Central Nervous System Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and stool samples
| Change in quality of life from before treatment to six months after treatment termination |
| Health-related Quality of Life (epileptic patients) | The change in participants' self-reported quality of life from before to after treatment, as measured by the QOLIE-31 questionnaire [Quality of life in epilepsy - 31 items]. The score consists of 7 domains which all are range from 0 to 100%. Those domains are: seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive, medication effects, social function. The seven domains are then summarized to an overall score by applying weights to each category. The overall score ranges from 0 to 100% with 100% being best possible quality of life. | Change in quality of life from before treatment to six months after treatment termination |
| Change in presence of T.solium-specific antigen | Change in presence of T.solium-specific antigen in the blood of patients with active neurocysticercosis | Change in presence of T.solium-specific antigen from before treatment to six months after treatment termination |
| D010272 | Parasitic Diseases |
| D003551 | Cysticercosis |
| D013622 | Taeniasis |
| D002590 | Cestode Infections |
| D006373 | Helminthiasis |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |